Overall survival among participants in the Prostate Cancer Prevention Trial

The Prostate Cancer Prevention Trial (PCPT) showed that treatment with finasteride (a 5α-reductase inhibitor) could lower the number of prostate cancers diagnosed in the U.S. each year by about 25 percent. … READ MORE …

Median OS of men with CRPC may have doubled since 2003

A new article in European Urology suggests that the mean life expectancy for men participating in recent clinical trials and expanded access programs for new drugs for the treatment of chemotherapy-naive, castration-resistant prostate cancer (CRPC) — including metastatic and non-metastatic patients — is now just over 30 months. … READ MORE …

The practical utility of prostate cancer survival and mortality data for clinicians and patients

Imagine that you are 65 years of age and have just been diagnosed with intermediate-risk prostate cancer (clinical stage T1c; PSA 3.7 ng/ml; Gleason 3 + 4 = 7; with 3/12 biopsy cores positive for cancer, all in the left lobe). You understand quickly that this places you at some risk for progressive disease, and perhaps even for prostate cancer-specific mortality. … READ MORE …

Brain metastasis, new drugs, and future treatment of mCRPC

A new article on the Medcape Oncology web site discusses progress in the treatment of metastatic, catsration-resistant prostate cancer (mCRPC) and the specific relationship between risk for brain metastasis and the extension of overall survival. … READ MORE …

Overall survival among chemo-naive, mCRPC patients in the abiraterone acetate Phase III trial

There appears to be a great deal of confusion about the overall survival (OS) data related to the recent approval of abiraterone acetate for chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). Let’s try to really clarify this. … READ MORE …

Long-term outcomes after RP as first-line therapy for men with cT3 disease at time of diagnosis

We have no data from randomized trials on the relative effectiveness of surgery compared to radiation therapy in the treatment of men initially diagnosed with clinical stage T3NxM0 prostate cancer. However, we do now have data from > 800 men treated with radical prostatectomy (RP) and followed for up to 23 years at the Mayo Clinic. … READ MORE …

Dr. Brawley’s views on survival of men with metastatic prostate cancer

Last week we reported data from a study by Tangen et al. suggesting that men diagnosed with metastatic prostate cancer are living longer today than they were in the 1980s and early 1990s. Frankly, we don’t find this finding particularly surprising. Why this is happening is a whole different issue. … READ MORE …

Increasing overall survival of men with metastatic disease

A paper in the October issue of the Journal of Urology offers an interesting analysis of the increase in median overall survival of men newly diagnosed with metastatic prostate cancer, not previously treated with androgen deprivation therapy (ADT), and enrolling in major clinical trials between 1985 and 2009. … READ MORE …

Keeping progress in perspective — a message to Prof. Alan Ashworth

With the publication of data about enzalutamide in the New England Journal of Medicine last week, Professor Alan Ashworth, the head of the Institute for Cancer Research (ICR) in the UK, proclaimed “a golden age in prostate cancer drug discovery.” … READ MORE …

Is salvage cryotherapy really as safe and effective as some suggest?

There have been an increasing number of articles published in the recent past suggesting salvage cryotherapy as an excellent option for the treatment of men with progressive prostate cancer after failure of first-line radiation therapy. … READ MORE …

Salvage ADT after failure of radiation therapy — the art of good timing

The art of good timing and good patient selection is important to the appropriate use of salvage hormone therapy in all men who are in biochemical failure after first- or second-line radiation therapy. A study published in “the Red Journal” helps to make this point. … READ MORE …

Appropriate identification and management of candidates for active surveillance

Three papers published on line in the Journal of Urology last week have meaningful implications for greater standardization of the ways physicians need to make decisions about the appropriate identification, selection, and management of candidates for active surveillance as compared to immediate therapy. … READ MORE …

Interpreting the data from the S9346/INT-0162 trial in hormone-sensitive, metastatic disease

We have already reported data, presented by Dr. Maha Hussain yesterday, that appear to show that — at least in men with clearly metastatic prostate cancer — continuous and complete androgen deprivation (CAD) extends survival significantly better than intermittent androgen deprivation (IAD). … READ MORE …

IAD vs. CAD in men with hormone-sensitive, metastatic prostate cancer

Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer. … READ MORE …

Abiraterone acetate in chemotherapy-naive mCRPC — Phase III trial outcome

This morning, at the ASCO annual meeting, Dr. Charles Ryan will present the full interim results of COU-AA-302, the randomized, Phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,113 other followers